Product Description
ACT-462206 is a new, potent, and selective dual orexin receptor antagonist (DORA) that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors. It decreases wakefulness and increases non-rapid eye movement (non-REM) and REM sleep while maintaining natural sleep architectures in rat and dog electroencephalography/electromyography (EEG/EMG) experiments. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25147058/)
Mechanisms of Action: OX1R Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01954589 |
AC-074-101 | P1 |
Completed |
Healthy Volunteers |
2012-01-01 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/26/2021 |
PubMed |
Hypothalamic kinin B1 receptor mediates orexin system hyperactivity in neurogenic hypertension. |
|
08/12/2020 |
PubMed |
20 Years of Medicinal Chemistry - Always Look at the Bright Side (of Life). |